Literature DB >> 21486371

Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo.

M Shafaati1, M Olin, A Båvner, H Pettersson, B Rozell, S Meaney, P Parini, I Björkhem.   

Abstract

BACKGROUND: Oxysterols such as 24S-hydroxycholesterol (OHC) and 27-OHC are intermediates of cholesterol excretion pathways. In addition, they are putative endogenous agonists of the liver X receptor (LXR) class of nuclear hormone receptors and are thought to be important mediators of cholesterol-dependent gene regulation. 24S-OHC is one of the most efficient endogenous LXR agonists known and is present in the brain and in the circulation at relatively high levels.
OBJECTIVES: To explore the regulatory importance of 24S-OHC in vivo.
DESIGN: We developed a transgenic mouse model in which human cholesterol 24-hydroxylase, the enzyme responsible for the formation of 24S-OHC, was expressed under the control of a promoter derived from the β-actin gene.
RESULTS: Both male and female transgenic mice had elevated levels of cerebral, plasma, biliary and faecal 24S-OHC. According to the faecal excretion results, production of 24S-OHC was increased four- to sevenfold. Gene expression profiling revealed that the elevated production of 24S-OHC did not result in the anticipated activation of LXR target genes in the brain or liver.
CONCLUSION: In spite of the fact that 24S-OHC is a highly effective agonist of LXRs in vitro, it is not a critical activator of target genes to this nuclear receptor in vivo, either in the brain or in the liver.
© 2011 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21486371     DOI: 10.1111/j.1365-2796.2011.02389.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  28 in total

1.  Sterol-dependent nuclear import of ORP1S promotes LXR regulated trans-activation of apoE.

Authors:  Sungsoo Lee; Ping-Yuan Wang; Yangsik Jeong; David J Mangelsdorf; Richard G W Anderson; Peter Michaely
Journal:  Exp Cell Res       Date:  2012-06-20       Impact factor: 3.905

2.  Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.

Authors:  Natalia Mast; Yong Li; Marlin Linger; Matthew Clark; Jeffrey Wiseman; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2013-12-18       Impact factor: 5.157

3.  Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Authors:  Natalia Mast; Aicha Saadane; Ana Valencia-Olvera; James Constans; Erin Maxfield; Hiroyuki Arakawa; Young Li; Gary Landreth; Irina A Pikuleva
Journal:  Neuropharmacology       Date:  2017-06-24       Impact factor: 5.250

Review 4.  Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.

Authors:  Alexey M Petrov; Irina A Pikuleva
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

5.  Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases.

Authors:  Irina A Pikuleva
Journal:  Explor Neuroprotective Ther       Date:  2021-12-30

6.  On the regulatory role of side-chain hydroxylated oxysterols in the brain. Lessons from CYP27A1 transgenic and Cyp27a1(-/-) mice.

Authors:  Zeina Ali; Maura Heverin; Maria Olin; Jure Acimovic; Anita Lövgren-Sandblom; Marjan Shafaati; Ann Båvner; Vardiella Meiner; Eran Leitersdorf; Ingemar Björkhem
Journal:  J Lipid Res       Date:  2013-01-02       Impact factor: 5.922

7.  Cholesterol 24S-Hydroxylase Overexpression Inhibits the Liver X Receptor (LXR) Pathway by Activating Small Guanosine Triphosphate-Binding Proteins (sGTPases) in Neuronal Cells.

Authors:  Miguel Moutinho; Maria João Nunes; Anita Q Gomes; Maria João Gama; Angel Cedazo-Minguez; Cecília M P Rodrigues; Ingemar Björkhem; Elsa Rodrigues
Journal:  Mol Neurobiol       Date:  2014-08-02       Impact factor: 5.590

Review 8.  LXR Regulation of Brain Cholesterol: From Development to Disease.

Authors:  Rebecca Courtney; Gary E Landreth
Journal:  Trends Endocrinol Metab       Date:  2016-04-21       Impact factor: 12.015

9.  In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine.

Authors:  Natalia Mast; Marlin Linger; Matthew Clark; Jeffrey Wiseman; C David Stout; Irina A Pikuleva
Journal:  Mol Pharmacol       Date:  2012-08-02       Impact factor: 4.436

Review 10.  The Controversial Role of 24-S-Hydroxycholesterol in Alzheimer's Disease.

Authors:  Paola Gamba; Serena Giannelli; Erica Staurenghi; Gabriella Testa; Barbara Sottero; Fiorella Biasi; Giuseppe Poli; Gabriella Leonarduzzi
Journal:  Antioxidants (Basel)       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.